Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. GOVX
stocks logo

GOVX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
0.00
-100%
-0.290
-3.33%
0.00
-100%
-0.350
-22.22%
0.00
-100%
-0.400
+14.29%
Estimates Revision
The market is revising No Change the revenue expectations for GeoVax Labs, Inc. (GOVX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -45.02%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+21.69%
In Past 3 Month
Stock Price
Go Down
down Image
-45.02%
In Past 3 Month
Wall Street analysts forecast GOVX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GOVX is 12.00 USD with a low forecast of 10.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast GOVX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GOVX is 12.00 USD with a low forecast of 10.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.384
sliders
Low
10.00
Averages
12.00
High
14.00
Current: 0.384
sliders
Low
10.00
Averages
12.00
High
14.00
Alliance Global Partners
Buy
maintain
$8.50
2025-06-18
Reason
Alliance Global Partners
Price Target
$8.50
2025-06-18
maintain
Buy
Reason
Alliance Global Partners reiterates a Buy rating and $8.50 price target on shares of GeoVax Labs, telling investors in a research note that the positive Scientific Advice from the European Medicines Agency regarding their GEO-MVA candidate vaccine for the prevention of Mpox and smallpox provides a clear regulatory pathway ahead, and if successful, could lead to a potential accelerated regulatory approval timeline. This feedback also comes as the World Health Organization issued its fourth declaration of Mpox as a Public Health Emergency of International Concern, further reiterating the need to create preventative measures for Mpox, the firm says.
HC Wainwright & Co.
Vernon Bernardino
Strong Buy
Reiterates
$8
2025-04-16
Reason
HC Wainwright & Co.
Vernon Bernardino
Price Target
$8
2025-04-16
Reiterates
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$18 → $14
2025-04-15
Reason
D. Boral Capital
Jason Kolbert
Price Target
$18 → $14
2025-04-15
Maintains
Strong Buy
Reason
D. Boral Capital lowered the firm's price target on GeoVax Labs to $14 from $18 and keeps a Buy rating on the shares. GeoVax has encountered a significant challenge following the termination of its BARDA-funded Phase 2b clinical trial for the GEO-CM04S1 COVID-19 vaccine, the firm says. This decision, made for the government's convenience, halts a pivotal study that was set to evaluate GEO-CM04S1 against an approved mRNA vaccine in a 10,000-participant trial under Project NextGen. The abrupt termination raises concerns about the future trajectory of GeoVax's vaccine development efforts and its financial implications, says D. Boral Capital. The firm has removed all BARDA revenues and stockpile awards that were in its model.
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$18
2025-04-10
Reason
D. Boral Capital
Jason Kolbert
Price Target
$18
2025-04-10
Maintains
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$18
2025-03-28
Reason
D. Boral Capital
Jason Kolbert
Price Target
$18
2025-03-28
Maintains
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$18
2025-02-27
Reason
D. Boral Capital
Jason Kolbert
Price Target
$18
2025-02-27
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for GeoVax Labs Inc (GOVX.O) is -0.26, compared to its 5-year average forward P/E of -1.61. For a more detailed relative valuation and DCF analysis to assess GeoVax Labs Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.61
Current PE
-0.26
Overvalued PE
-0.22
Undervalued PE
-3.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.41
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
2.47
Undervalued EV/EBITDA
-3.29

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
57.27
Current PS
0.00
Overvalued PS
174.97
Undervalued PS
-60.44
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

GOVX News & Events

Events Timeline

(ET)
2025-08-07
14:40:07
HHS mRNA vaccine decision bodes well for GeoVax Labs, says Roth Capital
select
2025-06-16 (ET)
2025-06-16
16:41:20
GeoVax Labs files to sell 6.15M common units
select
2025-06-16
10:59:06
GeoVax Labs receives favorable European regulatory guidance supporting GEO-MVA
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
10-18SeekingAlpha
GeoVax Labs Seeks Approval to Offer 11.9 Million Shares of Common Stock for Shareholders

  • Stock Offering Announcement: GeoVax Labs filed to sell 11.9 million shares of common stock for existing holders.

  • Preliminary Prospectus Note: The filing is a preliminary prospectus and does not constitute an offer to sell.

[object Object]
Preview
1.0
09-24Globenewswire
Live Stream Registration Now Open for Day 2 of the Emerging Growth Conference 86 on September 25

  • Emerging Growth Conference Announcement: The 86th Emerging Growth Conference is scheduled for September 24 & 25, 2025, focusing on companies with strong management and growth potential across various sectors.

  • Keynote Speakers and Schedule: The conference features multiple keynote speakers from various companies, including Kneat.com, Zapp Electric Vehicles, and Citizens, Inc., with sessions conducted via video webcasts.

[object Object]
Preview
1.0
08-19Globenewswire
Join the Live Stream of Day 1 at the Emerging Growth Conference 85 on August 20; Registration Now Open

  • Emerging Growth Conference Announcement: The 85th Emerging Growth Conference is scheduled for August 20 & 21, 2025, focusing on companies with strong management and growth potential across various sectors.

  • Day 1 Schedule Highlights: Keynote speakers include CEOs from companies such as Immuron Limited, Nutriband, Inc., and Journey Medical Corporation, presenting their innovative products and strategies.

  • Day 2 Schedule Highlights: Presentations will feature executives from Eshallgo, Inc., Grove Collaborative Holdings, Inc., and U.S. Energy Corporation, among others, discussing their business developments.

  • Engagement and Participation: Attendees can register for the conference, submit questions to presenting companies, and access replays via the EmergingGrowth.com platform.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is GeoVax Labs Inc (GOVX) stock price today?

The current price of GOVX is 0.3836 USD — it has decreased -4.24 % in the last trading day.

arrow icon

What is GeoVax Labs Inc (GOVX)'s business?

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. Its lead clinical program is GEO-CM04S1, a COVID-19 vaccine, which is in three phase II clinical trials, being evaluated as a primary vaccine for immunocompromised patients, such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient; a booster vaccine in patients with chronic lymphocytic leukemia (CLL); and a COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology, the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin, having completed a multicenter Phase I/II clinical trial for advanced head and neck cancers. It is developing GEO-MVA, a vaccine targeting Mpox and smallpox. Its other product candidates include GEO-EM01-Z, GEO-EM01-S, GEO-MM01, GEO-ZM02 and others.

arrow icon

What is the price predicton of GOVX Stock?

Wall Street analysts forecast GOVX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GOVX is 12.00 USD with a low forecast of 10.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is GeoVax Labs Inc (GOVX)'s revenue for the last quarter?

GeoVax Labs Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

arrow icon

What is GeoVax Labs Inc (GOVX)'s earnings per share (EPS) for the last quarter?

GeoVax Labs Inc. EPS for the last quarter amounts to -0.31 USD, decreased -65.93 % YoY.

arrow icon

What changes have occurred in the market's expectations for GeoVax Labs Inc (GOVX)'s fundamentals?

The market is revising No Change the revenue expectations for GeoVax Labs, Inc. (GOVX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -45.02%.
arrow icon

How many employees does GeoVax Labs Inc (GOVX). have?

GeoVax Labs Inc (GOVX) has 17 emplpoyees as of December 05 2025.

arrow icon

What is GeoVax Labs Inc (GOVX) market cap?

Today GOVX has the market capitalization of 11.39M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free